Precigen is a clinical-stage biopharmaceutical company advancing gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its main therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its lead clinical programs, including: PRGN-3005 and PRGN-3006, which are built on Co.'s UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on Co.'s AdenoVerse immunotherapy platform; and AG019, which is built on Co.'s ActoBiotics platform. Co. has developed a proprietary electroporation device, UltraPorator, designed to further streamline manufacturing of UltraCAR-T therapies. The PGEN stock yearly return is shown above.
The yearly return on the PGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|